AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2660997 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc chloride spray and magnesium hydroxide ointment applied twice daily for seven consecutive days
Number of subjects: 100
Study 2660997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31618267 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter group (case)
Number of subjects: 189
Study 31618267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study 28277603 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months during the FREEDOM trial
Number of subjects: 0
Study 28277603 — intervention group
Group type: COMPARATOR
Intervention: Denosumab during the FREEDOM Extension (Crossover Group)
Number of subjects: 0
Study 28277603 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab during the FREEDOM Extension (Long-term Group)
Number of subjects: 0
Study 25636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler
Number of subjects: 1971
Study 25636792 — intervention group
Group type: COMPARATOR
Intervention: Pinard
Number of subjects: 1971
Study 23408299 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 205
Study 23408299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 21493792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid therapy
Number of subjects: 28
Study 19112757 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg
Number of subjects: 15
Study 19112757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16442916 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP group (n = 119)
Number of subjects: 226
Study 16442916 — intervention group
Group type: COMPARATOR
Intervention: Clinical group (n = 107)
Number of subjects: 226
Study 16442916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 226
Study 15274684 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 33
Study 15274684 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 33
Study 15274684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril 10 mg and losartan 100 mg daily
Number of subjects: 33
Study 15274684 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 33
Study 11016325 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 microg/kg bolus plus 2 microg/kg/min infusion)
Number of subjects: 78
Study 11016325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8872656 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) - 75 g glucose solution ingested 30 min before exercise
Number of subjects: 6
Study 8872656 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) - sweet placebo solution ingested 30 min before exercise
Number of subjects: 6
Study 1618465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (5 gm twice daily)
Number of subjects: 74
Study 1618465 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (dose adjusted for 2 or 3 semiformed stools/day)
Number of subjects: 74
Study 1618465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 74
Study 6662184 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid
Number of subjects: 0
Study 6662184 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide-amiloride combination
Number of subjects: 0
Study 31965649 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin
Number of subjects: 203
Study 31965649 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose cefazolin (3 days)
Number of subjects: 203
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 0
Study 31504541 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia liability
Number of subjects: 0
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 0
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides in medium very-low-density lipoprotein (VLDL)
Number of subjects: 0
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides in large VLDL
Number of subjects: 0
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 0
Study 31504541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate
Number of subjects: 0
Study 28157791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (10 mL of liposome bupivacaine 133 mg) added to 5 mL of 0.25% bupivacaine HCl
Number of subjects: 52
Study 28157791 — intervention group
Group type: COMPARATOR
Intervention: Standard bupivacaine (15 mL of 0.25% bupivacaine HCl) alone
Number of subjects: 52
Study 27085587 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0
Study 27085587 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study 24332192 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity program (HB)
Number of subjects: 76
Study 24332192 — intervention group
Group type: COMPARATOR
Intervention: Group exercise program (G)
Number of subjects: 76
Study 21823282 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Tianshu (ST 25) and Dachangshu (BL 25), once daily for 4 weeks.
Number of subjects: 40
Study 21823282 — intervention group
Group type: COMPARATOR
Intervention: Trimebutine Maleate, 2 capsules, 3 times per day for 4 weeks.
Number of subjects: 40
Study 19141778 — intervention group
Group type: EXPERIMENTAL
Intervention: Double testing with cytology and type-specific HPV persistence
Number of subjects: 6257
Study 19141778 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary screening with HPV DNA testing followed by cytological triage and repeat HPV DNA testing
Number of subjects: 6257
Study 19141778 — intervention group
Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 6257
Study 17607003 — intervention group
Group type: EXPERIMENTAL
Intervention: C-allele at low levels of endotoxin exposure
Number of subjects: 0
Study 17607003 — intervention group
Group type: EXPERIMENTAL
Intervention: T-allele at high levels of endotoxin exposure
Number of subjects: 0
Study 17607003 — intervention group
Group type: EXPERIMENTAL
Intervention: C-allele homozygotes
Number of subjects: 0
Study 17607003 — intervention group
Group type: EXPERIMENTAL
Intervention: Other two genotypes (not specified)
Number of subjects: 0
Study 14709946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (Zoloft) 50 to 200 mg/d
Number of subjects: 204
Study 14709946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 11427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised lipoprotein (a) levels at baseline
Number of subjects: 1592
Study 11427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised lipoprotein (a) levels at baseline after adjustment for baseline cardiovascular disease and other risk factors
Number of subjects: 1592
Study 9732416 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeded grafts with transplanted microvessel cells
Number of subjects: 9
Study 9732416 — intervention group
Group type: COMPARATOR
Intervention: Nonseeded grafts
Number of subjects: 9
Study 8050691 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of vascular invasion
Number of subjects: 106
Study 8050691 — intervention group
Group type: COMPARATOR
Intervention: Absence of vascular invasion
Number of subjects: 106
Study 8050691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour vascular invasion
Number of subjects: 106
Study 2724108 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine (lidocaine hydrochloride) administered as a posterior tibial block
Number of subjects: 50
Study 2724108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorcaine (bupivacaine hydrochloride) administered as a posterior tibial block
Number of subjects: 50
Study 2724108 — intervention group
Group type: COMPARATOR
Intervention: Nerve blockade of remaining nerves of the foot
Number of subjects: 50
Study 31843791 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with macular ILM peeling
Number of subjects: 60
Study 31843791 — intervention group
Group type: COMPARATOR
Intervention: PPV alone (conventional treatment)
Number of subjects: 60
Study 30977904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.0 milliamps) combined with MBRP
Number of subjects: 84
Study 30977904 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (0.0 milliamps) combined with MBRP
Number of subjects: 84
Study 28427336 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modification intervention provided by an occupational therapist in addition to usual care
Number of subjects: 300
Study 28427336 — intervention group
Group type: COMPARATOR
Intervention: Usual care (continued services from the area agency on aging)
Number of subjects: 300
Study 28427336 — intervention group
Group type: EXPERIMENTAL
Intervention: Home modification intervention
Number of subjects: 300
Study 28427336 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation component of the study
Number of subjects: 300
Study 25442169 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games
Number of subjects: 9
Study 25442169 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycling
Number of subjects: 9
Study 22505295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (early scan of the wrist, discharged if no injury)
Number of subjects: 84
Study 22505295 — intervention group
Group type: COMPARATOR
Intervention: Control (reassessment in clinic)
Number of subjects: 84
Study 22505295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (early scan of the wrist)
Number of subjects: 84
Study 21821221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) curriculum
Number of subjects: 26
Study 21821221 — intervention group
Group type: COMPARATOR
Intervention: Traditional curriculum (Control)
Number of subjects: 26
Study 19497079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine plus artesunate (SP/AS)
Number of subjects: 296
Study 19497079 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate (AQ/AS)
Number of subjects: 296
Study 19497079 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 296
Study 19497079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine plus artesunate (SP/AS) and Amodiaquine plus artesunate (AQ/AS)
Number of subjects: 296
Study 16454979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (loading dose of 300 mg aspirin and 300 mg clopidogrel, then 100 mg aspirin and 75 mg clopidogrel per day)
Number of subjects: 115
Study 16454979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (loading dose of 300 mg aspirin, then 100 mg per day)
Number of subjects: 115
Study 16454979 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers on no medications)
Number of subjects: 115
Study 12641517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 56
Study 12641517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11056333 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 769
Study 11056333 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 769
Study 8957697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin E treatment
Number of subjects: 52
Study 8957697 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study 1533427 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels at study entry
Number of subjects: 331
Study 1533427 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP value greater than 200 pmol/L
Number of subjects: 331
Study 1533427 — intervention group
Group type: EXPERIMENTAL
Intervention: History of CHF in the previous year
Number of subjects: 331
Study 1533427 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification of cohort by ANP levels and history of CHF
Number of subjects: 331
Study 2410520 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazina (combination tablet of thiacetazone and INH) daily for 12 months
Number of subjects: 806
Study 2410520 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazina daily for 12 months plus rifampin daily during months 1 and 7
Number of subjects: 806
Study 2410520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin daily during months 1 and 7 but no Thiazina
Number of subjects: 806
Study 2410520 — intervention group
Group type: COMPARATOR
Intervention: Control group (dapsone monotherapy)
Number of subjects: 806
Study 29094283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for depression and anxiety
Number of subjects: 115
Study 29094283 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no CBT)
Number of subjects: 115
Study 29094283 — intervention group
Group type: COMPARATOR
Intervention: Non-CBT group
Number of subjects: 115
Study 29094283 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CBT, Comparison, Non-CBT)
Number of subjects: 115
Study 27768695 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX168 (30 mg orally, twice daily)
Number of subjects: 48
Study 27768695 — intervention group
Group type: EXPERIMENTAL
Intervention: CCX168 (1 to 100 mg)
Number of subjects: 48
Study 24456286 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPT; 20 μg s.c.) for 6 months
Number of subjects: 21
Study 24456286 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 21
Study 23321196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 3.75 mg/day
Number of subjects: 0
Study 23321196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg/day
Number of subjects: 0
Study 20837928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 42
Study 20837928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 0, 5, or 50 μmol/L ex vivo
Number of subjects: 42
Study 18432253 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 30
Study 18432253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 30
Study 16452128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group recruitment method after lectures
Number of subjects: 2500
Study 16452128 — intervention group
Group type: COMPARATOR
Intervention: Individual recruitment by researchers
Number of subjects: 2500
Study 12753596 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandage system (Profore)
Number of subjects: 112
Study 12753596 — intervention group
Group type: COMPARATOR
Intervention: Two-layer bandage system (Surepress)
Number of subjects: 112
Study 10440462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 3,600 mg daily in three divided doses)
Number of subjects: 69
Study 10440462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10440462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 69
Study 8773038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 56
Study 8773038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2276107 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care protocol A
Number of subjects: 18
Study 2276107 — intervention group
Group type: COMPARATOR
Intervention: Oral care protocol B
Number of subjects: 18
Study 2276107 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement of oral care instructions and nursing assessments
Number of subjects: 18
Study 2276107 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral white blood cell count
Number of subjects: 18
Study 427401 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief care (experimental group)
Number of subjects: 127
Study 427401 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 127
Study 31939712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobotomy (ATLo)
Number of subjects: 42
Study 31939712 — intervention group
Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATLe)
Number of subjects: 42
Study 31939712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 31121913 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglena gracilis EOD1BM ingestion
Number of subjects: 13
Study 31121913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28477678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led group clinic intervention
Number of subjects: 35
Study 28477678 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 35
Study 26471180 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAG)
Number of subjects: 70
Study 26471180 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OG)
Number of subjects: 70
Study 22883421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mcg/kg
Number of subjects: 162
Study 22883421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 mcg/kg
Number of subjects: 162
Study 22883421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 21160058 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/day)
Number of subjects: 36
Study 21160058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day)
Number of subjects: 36
Study 21160058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 0.5 mg twice daily (b.i.d.)
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 0.25 mg b.i.d. and 0.5 mg b.i.d.
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: All BIS regimens
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 0.25 mg once daily (q.d.)
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 0.5 mg q.d.
Number of subjects: 1018
Study 18534086 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 1.0 mg q.d.
Number of subjects: 1018
Study 18534086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1018
Study 17242413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of 0.2% ropivacaine hydrochloride (10 mL/h without bolus)
Number of subjects: 50
Study 17242413 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 mL of 0.2% ropivacaine hydrochloride per hour with 10-mL bolus)
Number of subjects: 50
Study 12598885 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 900 mg
Number of subjects: 167
Study 11396782 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive subjects
Number of subjects: 0
Study 9545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day, adjusted to 6.4 mg/day)
Number of subjects: 86
Study 9545995 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (300 mg/day, adjusted to 291.2 mg/day)
Number of subjects: 86
Study 9545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86
Study 9545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 8004600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography in the BCDDP (1970s)
Number of subjects: 93471
Study 8004600 — intervention group
Group type: COMPARATOR
Intervention: Mammography in the HIP study (1960s)
Number of subjects: 93471
Study 8004600 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual two-view mammography plus clinical breast examination
Number of subjects: 93471
Study 8004600 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of types, sizes, stage distributions, and survival rates
Number of subjects: 93471
Study 2574081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion
Number of subjects: 9
Study 2574081 — intervention group
Group type: COMPARATOR
Intervention: Control infusion (0.9% saline)
Number of subjects: 9
Study 819341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (Diamox)
Number of subjects: 25
Study 819341 — intervention group
Group type: COMPARATOR
Intervention: Control persons (not specified)
Number of subjects: 25
Study 7411761 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate or estolate, 500 mg orally every six hours for five days (13 patients)
Number of subjects: 23
Study 7411761 — intervention group
Group type: COMPARATOR
Intervention: Crystalline aqueous penicillin G potassium, 1 million units intravenously every three hours for three days (10 patients)
Number of subjects: 23
Study 31567921 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day dose of 4 L polyethylene glycol
Number of subjects: 339
Study 31567921 — intervention group
Group type: COMPARATOR
Intervention: Split-dose of 4 L polyethylene glycol (2 L at 9:00 PM the day before and 2 L at 7:00 AM or 10:00 AM)
Number of subjects: 339
Study 31567921 — intervention group
Group type: COMPARATOR
Intervention: Split-dose of 4 L polyethylene glycol
Number of subjects: 339
Study 29385967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led chronic disease self-management support (CDSMS) program
Number of subjects: 254
Study 29385967 — intervention group
Group type: COMPARATOR
Intervention: Control group (positive attention only)
Number of subjects: 254
Study 27004474 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBI (n=61)
Number of subjects: 123
Study 27004474 — intervention group
Group type: COMPARATOR
Intervention: Control (n=62)
Number of subjects: 123
Study 24580388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and maintenance (TIVA)
Number of subjects: 60
Study 24580388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and sevoflurane maintenance (MIXED)
Number of subjects: 60